Cytodyn Inc (CYDY)

[tmac20]

They are keeping with their timeline of submitting the 3 sections. The "one more section" they refer to is the clinical one that they stated 1st Qtr. 2022. I wonder what they submitted for the second section though. it is carefully worded to say "Major" sections and then it goes on to say that there is still some stuff hanging out on the second section:

VANCOUVER, Wash.--(BUSINESS WIRE)-- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced it has completed submission of all the major sections of CMC modules to FDA, some remaining supporting documentation will be submitted under Regional Information before the end of this week.

This seems a little muddy. Should have read:

We are pleased to announce the second section has been submitted and the FDA is reviewing it. We are now working on the third and final section. But that's not what it says. I do give them credit though, at least they knew they needed to do some type of PR about it.

We should see a PR by the end of the week when they finish the second section completely.